TG Therapeutics Inc (TGTX)

Debt-to-equity ratio

Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Long-term debt US$ in thousands 244,429 100,118 71,135 66,788 7,716
Total stockholders’ equity US$ in thousands 222,364 160,502 58,587 237,153 519,350
Debt-to-equity ratio 1.10 0.62 1.21 0.28 0.01

December 31, 2024 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $244,429K ÷ $222,364K
= 1.10

The debt-to-equity ratio for TG Therapeutics Inc has shown significant fluctuations over the past five years. Starting at a very low point of 0.01 on December 31, 2020, the ratio has steadily increased to 1.21 by December 31, 2022, more than doubling within a two-year period. This rapid increase in the ratio indicates a higher reliance on debt to finance the company's operations and growth initiatives.

However, in the subsequent year, by December 31, 2023, the ratio decreased to 0.62, which may suggest a decrease in the company's debt levels relative to its equity. Nonetheless, by December 31, 2024, the ratio climbed back up to 1.10, indicating a resurgence in the utilization of debt to fund operations or investments.

Overall, the trend in the debt-to-equity ratio for TG Therapeutics Inc suggests a fluctuating capital structure over the years, with the company shifting between periods of high and low reliance on debt financing compared to equity. Investors and stakeholders may want to closely monitor these changes to assess the company's financial risk and stability.